AVAX Technologies, Inc. (AVXT)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2007 | 3.99 Million USD | 47.9% |
| 2006 | 2.7 Million USD | 48.3% |
| 2005 | 1.82 Million USD | -24.96% |
| 2004 | 2.42 Million USD | -15.82% |
| 2003 | 2.88 Million USD | -21.76% |
| 2002 | 3.68 Million USD | 46.71% |
| 2001 | 2.51 Million USD | -3.76% |
| 2000 | 2.6 Million USD | 552.25% |
| 1999 | 400 Thousand USD | -50.0% |
| 1998 | 800 Thousand USD | -50.0% |
| 1997 | 1.6 Million USD | -36.0% |
| 1996 | 2.5 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2008 Q1 | 3.43 Million USD | -13.98% |
| 2008 Q2 | 3.03 Million USD | -11.74% |
| 2008 Q3 | 3.45 Million USD | 13.87% |
| 2007 Q3 | 3.93 Million USD | 16.77% |
| 2007 Q1 | 3.29 Million USD | 21.87% |
| 2007 Q2 | 3.36 Million USD | 2.4% |
| 2007 FY | 3.99 Million USD | 47.9% |
| 2007 Q4 | 3.99 Million USD | 1.5% |
| 2006 Q2 | 2.1 Million USD | 4.25% |
| 2006 Q3 | 2.21 Million USD | 5.2% |
| 2006 FY | 2.7 Million USD | 48.3% |
| 2006 Q4 | 2.7 Million USD | 21.72% |
| 2006 Q1 | 2.02 Million USD | 11.09% |
| 2005 Q4 | 1.82 Million USD | -2.85% |
| 2005 Q1 | 4.06 Million USD | 67.46% |
| 2005 Q2 | 2.51 Million USD | -38.04% |
| 2005 FY | 1.82 Million USD | -24.96% |
| 2005 Q3 | 1.87 Million USD | -25.56% |
| 2004 FY | 2.42 Million USD | -15.82% |
| 2004 Q4 | 2.42 Million USD | 3.64% |
| 2004 Q1 | 3.4 Million USD | 18.25% |
| 2004 Q2 | 2.4 Million USD | -29.57% |
| 2004 Q3 | 2.34 Million USD | -2.47% |
| 2003 Q4 | 2.88 Million USD | 94.54% |
| 2003 Q1 | 2.28 Million USD | -37.93% |
| 2003 FY | 2.88 Million USD | -21.76% |
| 2003 Q3 | 1.48 Million USD | 8.84% |
| 2003 Q2 | 1.36 Million USD | -40.47% |
| 2002 Q3 | 2.67 Million USD | 16.13% |
| 2002 Q1 | 2.28 Million USD | -8.96% |
| 2002 FY | 3.68 Million USD | 46.71% |
| 2002 Q4 | 3.68 Million USD | 37.81% |
| 2002 Q2 | 2.3 Million USD | 0.69% |
| 2001 FY | 2.51 Million USD | -3.76% |
| 2001 Q4 | 2.51 Million USD | 20.57% |
| 2001 Q1 | 1.71 Million USD | -34.42% |
| 2001 Q3 | 2.08 Million USD | 25.02% |
| 2001 Q2 | 1.66 Million USD | -2.64% |
| 2000 Q4 | 2.6 Million USD | 14.12% |
| 2000 Q2 | 798.83 Thousand USD | 7.86% |
| 2000 Q3 | 2.28 Million USD | 186.2% |
| 2000 FY | 2.6 Million USD | 552.25% |
| 2000 Q1 | 740.59 Thousand USD | 85.15% |
| 1999 Q3 | 500 Thousand USD | -16.67% |
| 1999 Q2 | 600 Thousand USD | -33.33% |
| 1999 Q1 | 900 Thousand USD | 12.5% |
| 1999 FY | 400 Thousand USD | -50.0% |
| 1999 Q4 | 400 Thousand USD | -20.0% |
| 1998 Q1 | 300 Thousand USD | -81.25% |
| 1998 Q2 | 300 Thousand USD | 0.0% |
| 1998 Q3 | 400 Thousand USD | 33.33% |
| 1998 Q4 | 800 Thousand USD | 100.0% |
| 1998 FY | 800 Thousand USD | -50.0% |
| 1997 Q1 | 1.5 Million USD | 0.0% |
| 1997 FY | 1.6 Million USD | -36.0% |
| 1997 Q4 | 1.6 Million USD | 6.67% |
| 1997 Q2 | 1.4 Million USD | -6.67% |
| 1997 Q3 | 1.5 Million USD | 7.14% |
| 1996 FY | 2.5 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -14458.178% |
| Arch Therapeutics, Inc. | 9.46 Million USD | 57.809% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 94.489% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -393.79% |
| Rebus Holdings, Inc. | 5.24 Million USD | 23.813% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 93.233% |
| Qrons Inc. | 1.48 Million USD | -168.268% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 1.22 Million USD | -225.697% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 94.669% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -8835.352% |
| Skye Bioscience, Inc. | 14.07 Million USD | 71.62% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 92.508% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 58.32% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -847.355% |
| SQZ Biotechnologies Company | 50.03 Million USD | 92.019% |
| Intellipharmaceutics International Inc. | 12 Million USD | 66.743% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -3.695% |
| Mesoblast Limited | 188.44 Million USD | 97.881% |
| Marizyme, Inc. | 26.67 Million USD | 85.029% |
| Genus plc | 485 Million USD | 99.177% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | 31.645% |
| Pharming Group N.V. | 244.07 Million USD | 98.364% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -98.681% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -58.713% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -5.099% |
| ContraFect Corporation | 32.53 Million USD | 87.723% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -101.571% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -4.339% |
| IMV Inc. | 37.93 Million USD | 89.472% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 66.092% |
| MultiCell Technologies, Inc. | 1617.67 USD | -246782.553% |
| ONE Bio Corp. | 27.49 Million USD | 85.475% |
| Accustem Sciences Inc. | 1.07 Million USD | -270.052% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 94.841% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | -88.823% |
| Q BioMed Inc. | 8.13 Million USD | 50.894% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 95.184% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | 22.392% |
| Biomind Labs Inc. | 1.49 Million USD | -166.496% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 96.636% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | 55.832% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 78.299% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -178.531% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -2710.616% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -1885.792% |
| Curative Biotechnology, Inc. | 5.74 Million USD | 30.493% |
| GB Sciences, Inc. | 5.41 Million USD | 26.281% |
| Alpha Cognition Inc. | 7.16 Million USD | 44.259% |
| HST Global, Inc. | 593.59 Thousand USD | -572.809% |
| CSL Limited | 18.62 Billion USD | 99.979% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -217.167% |
| Halberd Corporation | 728.71 Thousand USD | -448.05% |
| Enzolytics Inc. | 365.26 Million USD | 98.907% |
| Agentix Corp. | 2.51 Million USD | -59.078% |
| Resverlogix Corp. | 67.39 Million USD | 94.074% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -376.165% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 99.102% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -133.007% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 83.861% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 66.448% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -8.965% |
| Zenith Capital Corp. | 27.56 Thousand USD | -14386.361% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.699% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -1573.446% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -6.947% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -486.596% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -47.281% |
| Kadimastem Ltd | 3.5 Million USD | -13.949% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -5867.137% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 92.054% |
| BioStem Technologies, Inc. | 15.9 Million USD | 74.889% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -759.426% |
| LadRx Corporation | 2.2 Million USD | -81.49% |
| Cell Source, Inc. | 15.8 Million USD | 74.734% |
| Regen BioPharma, Inc. | 5.45 Million USD | 26.823% |
| Regen BioPharma, Inc. | 5.45 Million USD | 26.823% |
| NovAccess Global Inc. | 7.86 Million USD | 49.194% |
| Affymax, Inc. | 8.87 Million USD | 54.98% |
| Itoco Inc. | 1.65 Million USD | -141.584% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -94.668% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | 33.977% |
| Mobile Lads Corp. | 1.31 Million USD | -204.054% |
| CytoDyn Inc. | 127.89 Million USD | 96.877% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -9454.642% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -154.967% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 63.842% |
| SYBLEU INC | 681.41 Thousand USD | -486.098% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | 34.549% |
| International Stem Cell Corporation | 5.27 Million USD | 24.318% |
| Bioxytran, Inc. | 3.24 Million USD | -22.903% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -538.173% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | 13.501% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 90.258% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 82.063% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -97.184% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | 27.095% |
| Neutra Corp. | 973.52 Thousand USD | -310.234% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 86.236% |
| PureTech Health plc | 125.58 Million USD | 96.82% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -6.298% |
| IXICO plc | 1.9 Million USD | -110.165% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 80.546% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 96.135% |
| CSL Limited | 18.62 Billion USD | 99.979% |
| Cellectis S.A. | 249.36 Million USD | 98.398% |